← Back to Screener
Biomea Fusion, Inc. Common Stock (BMEA)
Price$1.93
Favorite Metrics
Price vs S&P 500 (26W)13.28%
Price vs S&P 500 (4W)62.55%
Market Capitalization$142.43M
All Metrics
Book Value / Share (Quarterly)$0.41
P/TBV (Annual)3.45x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.97
Price vs S&P 500 (YTD)56.23%
EPS (TTM)$-1.52
10-Day Avg Trading Volume2.13M
EPS Excl Extra (TTM)$-1.52
EPS (Annual)$-1.18
ROI (Annual)-209.11%
Cash / Share (Quarterly)$0.77
ROA (Last FY)-105.51%
EBITD / Share (TTM)$-1.19
ROE (5Y Avg)-129.09%
Cash Flow / Share (Annual)$-0.97
P/B Ratio4.82x
P/B Ratio (Quarterly)2.97x
Net Income / Employee (Annual)$-1
ROA (TTM)-102.15%
EPS Incl Extra (Annual)$-1.18
Current Ratio (Annual)5.23x
Quick Ratio (Quarterly)5.03x
3-Month Avg Trading Volume1.38M
52-Week Price Return21.60%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$5.59
52-Week High$3.08
EPS Excl Extra (Annual)$-1.18
26-Week Price Return17.26%
Quick Ratio (Annual)5.03x
13-Week Price Return34.93%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)5.23x
Enterprise Value$86.618
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.77
3-Month Return Std Dev94.39%
Net Income / Employee (TTM)$-1
ROE (Last FY)-209.11%
EPS Basic Excl Extra (Annual)$-1.18
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.52
ROI (TTM)-243.73%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$3.67
Price vs S&P 500 (52W)-8.23%
Year-to-Date Return58.87%
5-Day Price Return6.49%
EPS Normalized (Annual)$-1.18
ROA (5Y Avg)-84.60%
Month-to-Date Return28.76%
Cash Flow / Share (TTM)$-3.27
EBITD / Share (Annual)$-1.19
ROI (5Y Avg)-129.09%
EPS Basic Excl Extra (TTM)$-1.52
P/TBV (Quarterly)1.87x
P/B Ratio (Annual)2.97x
Book Value / Share (Annual)$0.41
Price vs S&P 500 (13W)34.24%
Beta-0.10x
Revenue / Share (TTM)$0.00
ROE (TTM)-243.73%
52-Week Low$0.87
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.15
4.15
4.15
4.15
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
BMEABiomea Fusion, Inc. Common Stock | — | — | — | — | $1.93 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Biomea Fusion is a clinical-stage biopharmaceutical company developing oral small-molecule therapies for diabetes and obesity. Its lead candidate, icovamenib, is a covalent menin inhibitor in clinical trials for type 1 and type 2 diabetes and obesity, while BMF-650, an oral GLP-1 receptor agonist, is in development for the same indications. The company leverages its proprietary FUSION System platform to discover novel drug candidates targeting metabolic diseases.